Trulicity® is a GLP-1 RA that offers adults with type 2 diabetes

Proven HbA1c reduction 1

Ready-to-use pen 1

Once-weekly dosing 2

Trulicity® is a GLP-1 RA that offers adults with type 2 diabetes

Proven HbA1c reduction 1

Ready-to-use pen 1

Once-weekly dosing 2

Glycaemic Control
Trulicity Pen
Weight and safety
Trulicity SMPC

Trulicity Pen

Dosing that fits into a busy life:

A ready-to-use pen designed with patients in mind:

Administration that 99% of patients found easy2,3 :

  1. Uncap.
  2. Place and unlock.
  3. Press and hold.


99.1% of 211 injection-naive patients were successfully self-injecting after 3 weeks3 :

  • After their initial training, 97.2% of patients could successfully self-inject Trulicity
  • Fear of self-injecting had declined significantly
  • 96.7% of patients were willing to continue using the ready-to-use pen


video
Explore the science behind Trulicity:

Discover how the dulaglutide molecule was designed with the patient in mind.

Abbreviated Prescribing Information

Review the abbreviated prescribing information for Trulicity.


References

  1. Trulicity [Summary of Product Characteristics]. Houten, The Netherlands: Eli Lilly and Company; 2014.
  2. Trulicity Instructions for Use.
  3. Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial [published correction appears in Lancet. 2014;384:1348]. Lancet. 2014;384:1349-1357.
  4. Umpierrez G, Tofé Povedano S, Pérez Manghi F, et al. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014;37:2168-2176.
  5. Giorgino F, Benroubi M, Sun JH, et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care. 2015;38(12):2241-2249.
  6. Blonde L, Jendle J, Gross J, et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomized, open-label, phase 3, non-inferiority study. Lancet. 2015;385:2057-2066.